Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 3Glioma 2Glioblastoma 2Cholangiocarcinoma 2Targeted Therapy 1Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancies 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Gemcitabine 40Cisplatin 24Capecitabine 21Fluorouracil 19Oxaliplatin 17Leucovorin 14pembrolizumab 9Irinotecan 8Radiotherapy 7Erlotinib Hydrochloride 7durvalumab 6Sorafenib 4Magnetic Resonance Spectroscopy 4Carboplatin 4trametinib 3Trastuzumab 3Photochemotherapy 3Long-Term Synaptic Depression 3Interleukin-12 Subunit p35 3Filgrastim 3Dihematoporphyrin Ether 3Dexamethasone 3Chemotherapy, Adjuvant 3trifluridine tipiracil drug combination 2tivozanib 2tislelizumab 2spartalizumab 2regorafenib 2olaparib 2dehydroftorafur 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bile Duct Neoplasms × olutasidenib × Clear all
NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡